0001193125-15-032074.txt : 20150317 0001193125-15-032074.hdr.sgml : 20150317 20150203195334 ACCESSION NUMBER: 0001193125-15-032074 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20150203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INOTEK PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0001281895 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVE STREET 2: 1ST FLOOR, SUITE 105 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-676-2100 MAIL ADDRESS: STREET 1: 131 HARTWELL AVE STREET 2: 1ST FLOOR, SUITE 105 CITY: LEXINGTON STATE: MA ZIP: 02421 CORRESP 1 filename1.htm CORRESP

VIA EDGAR

February 3, 2015

United State Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 4720

100 F Street, N.E.

Washington, D.C. 20549

Attn:  Jeffrey P. Riedler

  Austin Stephenson

 

Re: Inotek Pharmaceuticals Corporation (the “Company”)
     Registration Statement on Form S-1 File No. 333-199859

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), and as representatives of the several underwriters of the Company’s proposed public offering of shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) and proposed offering of the Company’s convertible senior notes due 2020 (the “Convertible Notes”), we hereby join the Company’s request for acceleration of the effective date of the above-referenced Registration Statement, as amended, requesting effectiveness for 4:00 p.m. (ET) on February 5, 2015, or as soon thereafter as practicable.

Pursuant to Rule 460 of the Act, we wish to advise you that we have distributed approximately 1,400 copies of the Company’s preliminary prospectus relating to the Common Stock, dated January 21, 2015, and approximately 1,075 copies of the Company’s preliminary prospectus relating to the Convertible Notes, dated January 21, 2015, through the date hereof to underwriters, dealers, institutions and others.

The undersigned, as representatives of the several underwriters, have complied and will continue to comply, and have been informed by the participating underwriters that they have complied and will continue to comply, with the provisions of Rule 15c2-8 of the Securities Exchange Act of 1934, as amended.

[Signature page follows]

Very truly yours,  

COWEN AND COMPANY, LLC

PIPER JAFFRAY & CO.

NOMURA SECURITIES INTERNATIONAL, INC.

  

Acting on their own behalf

and as representatives of several

underwriters

  

 

BY: COWEN AND COMPANY, LLC
By:   /s/ Grant Miller
 

Name: Grant Miller

Title: Managing Director

 

BY: PIPER JAFFRAY & CO.

By:   /s/ Christie L. Christina
 

Name: Christie L. Christina

Title: Managing Director

 

By: NOMURA SECURITIES INTERNATIONAL, INC.
By:   /s/ Arun Master
 

Name: Arun Master

Title: Managing Director